Axitinib manufacturers & suppliers

Axitinib

Form: Tablets

Strength: 1 mg, 5 mg

Reference Brands: Inlyta®(EU & US)

Category: Oncology Cancer Care

Axitinib 1 mg and 5 mg Tablets are a key treatment for metastatic renal cell carcinoma (RCC), primarily used as a second-line therapy for patients who have failed prior treatments like sunitinib or pazopanib. As a tyrosine kinase inhibitor, Axitinib targets the VEGF receptors involved in tumor angiogenesis, thus slowing the growth of cancer cells. Approved under the brand name Inlyta® in both the U.S. and EU, Axitinib is essential in oncology B2B portfolios for advanced RCC treatment. It is typically administered twice daily in oral tablet form at doses of 1 mg or 5 mg.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Atezolizumab

Strength: 1200 mg/20 mL

Form: Intravenous infusion

Reference Brands: Tecentriq® (EU & US)

View Details
Durvalumab

Strength: 120 mg/4 mL, 500 mg/10 mL

Form: Injection

Reference Brands: Imfinzi® (US & EU)

View Details
Sunitinib

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg

Form: Tablet

Reference Brands: Sutent® (EU & US)

View Details
Ifosfamide

Strength: 1 g/vial,2 g/vial, 3 g/vial

Form: Injection

Reference Brands: Ifex® (US), Holoxan® (EU)

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.